177 related articles for article (PubMed ID: 35017371)
21. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.
Casaluce F; Sgambato A; Maione P; Rossi A; Ferrara C; Napolitano A; Palazzolo G; Ciardiello F; Gridelli C
Target Oncol; 2013 Mar; 8(1):55-67. PubMed ID: 23325296
[TBL] [Abstract][Full Text] [Related]
22. Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
Su Y; Long X; Song Y; Chen P; Li S; Yang H; Wu P; Wang Y; Bing Z; Cao Z; Cao L; Wu Y; Zhang Z; Liu J; Li B; Xiang J; Ma K; Zhang T; Zhang L; Mao X; Liu H; Xing P; Liang N
Target Oncol; 2019 Apr; 14(2):159-168. PubMed ID: 30895431
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study.
Kang J; Deng QM; Peng KC; Li P; Zhu BT; Wang P; Chu XP; Zhong WZ; Chen HJ; Wang WX; Chen HF; Rao CZ; Xu CW; Yang JJ
Genes Chromosomes Cancer; 2022 Apr; 61(4):177-186. PubMed ID: 34687488
[TBL] [Abstract][Full Text] [Related]
24. Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.
Ock CY; Yoo SH; Keam B; Kim M; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS
Korean J Intern Med; 2019 Sep; 34(5):1116-1124. PubMed ID: 29950554
[TBL] [Abstract][Full Text] [Related]
25. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
Horn L; Wang Z; Wu G; Poddubskaya E; Mok T; Reck M; Wakelee H; Chiappori AA; Lee DH; Breder V; Orlov S; Cicin I; Cheng Y; Liu Y; Fan Y; Whisenant JG; Zhou Y; Oertel V; Harrow K; Liang C; Mao L; Selvaggi G; Wu YL
JAMA Oncol; 2021 Nov; 7(11):1617-1625. PubMed ID: 34473194
[TBL] [Abstract][Full Text] [Related]
26. Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis.
Asao T; Fujiwara Y; Itahashi K; Kitahara S; Goto Y; Horinouchi H; Kanda S; Nokihara H; Yamamoto N; Takahashi K; Ohe Y
Clin Lung Cancer; 2017 Jul; 18(4):e251-e258. PubMed ID: 28065466
[TBL] [Abstract][Full Text] [Related]
27. Low ALK FISH positive metastatic non-small cell lung cancer (NSCLC) patients have shorter progression-free survival after treatment with ALK inhibitors.
Toruner GA; Tang Z; Tang G; Medeiros LJ; Hu S
Cancer Genet; 2020 Feb; 241():57-60. PubMed ID: 31870845
[TBL] [Abstract][Full Text] [Related]
28. Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study.
Gobbini E; Chiari R; Pizzutillo P; Bordi P; Ghilardi L; Pilotto S; Osman G; Cappuzzo F; Cecere F; Riccardi F; Scotti V; Martelli O; Borra G; Maiello E; Rossi A; Graziano P; Gregorc V; Casartelli C; Sergi C; Del Conte A; Delmonte A; Bareggi C; Cortinovis D; Rizzo P; Tabbò F; Rossi G; Bria E; Galetta D; Tiseo M; Di Maio M; Novello S
Clin Transl Oncol; 2020 Mar; 22(3):294-301. PubMed ID: 31630357
[TBL] [Abstract][Full Text] [Related]
29. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
Kim DW; Mehra R; Tan DSW; Felip E; Chow LQM; Camidge DR; Vansteenkiste J; Sharma S; De Pas T; Riely GJ; Solomon BJ; Wolf J; Thomas M; Schuler M; Liu G; Santoro A; Sutradhar S; Li S; Szczudlo T; Yovine A; Shaw AT
Lancet Oncol; 2016 Apr; 17(4):452-463. PubMed ID: 26973324
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of crizotinib in ALK mutant non-small cell lung cancers that are positive by IHC but negative by FISH compared to FISH positive cases.
Zanwar S; Noronha V; Joshi A; Patil VM; Kaushal R; Chougule A; Janu A; Mahajan A; Kapoor A; Prabhash K
Indian J Cancer; 2017; 54(4):678-680. PubMed ID: 30082557
[TBL] [Abstract][Full Text] [Related]
31. Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer.
Hong X; Chen Q; Ding L; Liang Y; Zhou N; Fang W; Chen X; Wu H
Oncotarget; 2017 Jun; 8(25):41631-41640. PubMed ID: 28427213
[TBL] [Abstract][Full Text] [Related]
32. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.
Kron A; Alidousty C; Scheffler M; Merkelbach-Bruse S; Seidel D; Riedel R; Ihle MA; Michels S; Nogova L; Fassunke J; Heydt C; Kron F; Ueckeroth F; Serke M; Krüger S; Grohe C; Koschel D; Benedikter J; Kaminsky B; Schaaf B; Braess J; Sebastian M; Kambartel KO; Thomas R; Zander T; Schultheis AM; Büttner R; Wolf J
Ann Oncol; 2018 Oct; 29(10):2068-2075. PubMed ID: 30165392
[TBL] [Abstract][Full Text] [Related]
33. Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report.
Guisier F; Piton N; Bellefleur M; Delberghe N; Avenel G; Angot E; Vittecoq O; Ould-Slimane M; Morisse-Pradier H; Salaun M; Thiberville L
BMC Cancer; 2020 Jan; 20(1):14. PubMed ID: 31906956
[TBL] [Abstract][Full Text] [Related]
34. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
Kuo CS; Tung PH; Huang AC; Wang CC; Chang JW; Liu CY; Chung FT; Fang YF; Guo YK; Yang CT
BMC Cancer; 2021 Mar; 21(1):309. PubMed ID: 33761908
[TBL] [Abstract][Full Text] [Related]
35. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
Kazandjian D; Blumenthal GM; Chen HY; He K; Patel M; Justice R; Keegan P; Pazdur R
Oncologist; 2014 Oct; 19(10):e5-11. PubMed ID: 25170012
[TBL] [Abstract][Full Text] [Related]
36. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
[TBL] [Abstract][Full Text] [Related]
37. Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.
Hembrough T; Liao WL; Hartley CP; Ma PC; Velcheti V; Lanigan C; Thyparambil S; An E; Monga M; Krizman D; Burrows J; Tafe LJ
Clin Chem; 2016 Jan; 62(1):252-61. PubMed ID: 26585927
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy and Safety of Crizotinib in Advanced or Recurrent
ALK-positive Non-small Cell Lung Cancer].
Li X; Xu H; Gao F; Kang X; Zhang J; Zhao J; Lin Y; Liu X
Zhongguo Fei Ai Za Zhi; 2019 Aug; 22(8):488-493. PubMed ID: 31451138
[TBL] [Abstract][Full Text] [Related]
39. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
40. Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
Chen RL; Zhao J; Zhang XC; Lou NN; Chen HJ; Yang X; Su J; Xie Z; Zhou Q; Tu HY; Zhong WZ; Yan HH; Guo WB; Wu YL; Yang JJ
BMC Cancer; 2018 Nov; 18(1):1171. PubMed ID: 30477470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
